AI Terminal
Elanix Biotechnologies AG
Director's Dealing • Nov 23, 2018
136_rns_2018-11-23_fa005505-19fd-46a2-89c1-2b941a315ebe.html
Director's Dealing
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 23 November 2018 22:34
Elanix Biotechnologies AG: Professor Laurent-Applegate, founder and Interim-CEO, announces sale of shares in Elanix Biotechnologies AG
Elanix Biotechnologies AG / Key word(s): Miscellaneous
Elanix Biotechnologies AG: Professor Laurent-Applegate, founder and Interim-CEO, announces sale of shares in Elanix Biotechnologies AG
23-Nov-2018 / 22:34 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Elanix Biotechnologies AG: Professor Laurent-Applegate, founder and Interim-CEO, announces sale of shares in Elanix Biotechnologies AG
Berlin, 23 November 2018 – Professor Laurent-Applegate, founder and Interim-CEO, has notified Elanix Biotechnologies AG (“Elanix” or the “Company”) that she intends to sell and transfer a total of 1,434,872 shares of Elanix. This is equivalent to approx. 17.8 per cent of the Company’s issued share capital. The shares shall be sold to a potential strategic investor. The purchase price is EUR 1.00 which is significantly below the current market price.
Lee Ann Laurent-Applegate
CEO
Contacts
Elanix Biotechnologies AG
Lee Ann Laurent-Applegate
Tel: +41 (0)22 363 66 40
About Elanix
Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.
Elanix has registered headquarters in Berlin, Germany, with offices in Wiesbaden, Germany and Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more information and updates, visit www.elanixbiotechnologies.com
Forward-looking statements
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
23-Nov-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Elanix Biotechnologies AG |
| Kurfürstendamm 32 | |
| 10719 Berlin | |
| Germany | |
| Phone: | +41 22 363 66 40 |
| Fax: | +41 22 363 66 41 |
| E-mail: | [email protected] |
| Internet: | www.elanixbiotechnologies.com |
| ISIN: | DE000A0WMJQ4 |
| WKN: | A0WMJQ |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf |
| End of Announcement | DGAP News Service |